Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 2:04 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 1,639 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Functional Medicine Clear all
Terminated Phase 2 Interventional Results available

Digoxin In Treatment of Alcohol Associated Hepatitis

NCT05014087
View directory record Official record
Conditions
Acute Alcoholic Hepatitis, Chemical and Drug Induced Liver Injury, Alcohol-Induced Disorders, Steatohepatitis Caused by Ingestible Alcohol
Interventions
Intravenous digoxin
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 16, 2026, 2:04 AM EDT
Terminated Not applicable Interventional

Reversible Pulmonary Artery Banding as Simplified Management of End-stage Dilated Left Ventriculopathy in Early Life

NCT02652676
View directory record Official record
Conditions
Acute on Chronic Systolic Congestive Heart Failure
Interventions
Reversible Pulmonary Artery Banding, GORE-TEX DualMesh EMERGE PLUS Biomaterial
Procedure
Lead sponsor
Loma Linda University
Other
Eligibility
Up to 4 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Feb 10, 2023 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

PharmacofMRI (Functional Magnetic Resonance Imaging) of Anxiolytic Medications (Alprazolam)

NCT00703885
View directory record Official record
Conditions
Anxiety Disorders
Interventions
0.25 mg alprazolam, 1.0 mg alprazolam, placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

Expanded Access to Diagnostic Imaging for Staging of Recurrent Prostate Cancer

NCT02260817
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
11C-choline Injection
Drug
Lead sponsor
Global Isotopes, LLC d/b/a Zevacor Molecular
Industry
Eligibility
18 Years and older · Male only
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Decatur, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

DPP4 Inhibition & Beta Cell Function

NCT02683187
View directory record Official record
Conditions
Healthy
Interventions
Active Comparator: Sitagliptin, Placebo Comparator - No Sitagliptin
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
35 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Results available

A Trial of Sertraline vs. CBT for End-stage Renal Disease Patients With Depression {ASCEND}

NCT02358343
View directory record Official record
Conditions
Depression, End Stage Renal Disease
Interventions
Engagement Interview, Cognitive Behavioral Therapy, Antidepressant Drug Therapy
Behavioral · Drug
Lead sponsor
University of Washington
Other
Eligibility
21 Years and older
Enrollment
184 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Albuquerque, New Mexico • Dallas, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Results available

Treating Negative Affect in Low Back Pain Patients

NCT04747314
View directory record Official record
Conditions
Chronic Low Back Pain, Negative Affectivity
Interventions
Antidepressant, Enhanced Fear Avoidance Rehabilitation
Drug · Other
Lead sponsor
Ajay Wasan, MD, Msc
Other
Eligibility
18 Years to 75 Years
Enrollment
308 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Chestnut Hill, Massachusetts • Rochester, Minnesota • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 16, 2026, 2:04 AM EDT
Recruiting Phase 1Phase 2 Interventional

Double Dose 4-AP on Functional Recovery After Spinal Cord Injury

NCT06853015
View directory record Official record
Conditions
SCI - Spinal Cord Injury
Interventions
Dalfampridine, Placebo, STDP stimulation, Exercise training
Drug · Other · Behavioral
Lead sponsor
Shirley Ryan AbilityLab
Other
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 3, 2026 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Not applicable Interventional Results available

Evaluation of Etomidate on Adrenal Function in Trauma Patients

NCT00462644
View directory record Official record
Conditions
Adrenal Insufficiency
Interventions
RSI sedation with etomidate/succinylcholine, RSI sedation with fentanyl/midazolam/succinylcholine
Drug
Lead sponsor
University of Tennessee
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Chattanooga, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Oct 16, 2026, 2:04 AM EDT
Terminated No phase listed Observational Results available

Pharmacogenomics for Antidepressant Guidance and Education

NCT01555021
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Genotyping assays
Genetic
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Treating Hyperexcitability in AD With Levetiracetam

NCT03875638
View directory record Official record
Conditions
Alzheimer Dementia, Alzheimer Disease, Dementia of Alzheimer Type, Mild Cognitive Impairment
Interventions
Levetiracetam, Placebo oral capsule
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 90 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 1 Interventional

Family Check-Up for Adolescents and Siblings

NCT00925340
View directory record Official record
Conditions
Alcohol Abuse
Interventions
Family Check Up, Psychoeducation
Behavioral
Lead sponsor
Brown University
Other
Eligibility
12 Years to 18 Years
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 29, 2014 · Synced Oct 16, 2026, 2:04 AM EDT
Withdrawn No phase listed Observational

Ovarian Damage in Young Premenopausal Women Undergoing Chemotherapy for Cancer

NCT00402935
View directory record Official record
Conditions
Leukemia, Long-term Effects Secondary to Cancer Therapy in Adults, Long-term Effects Secondary to Cancer Therapy in Children, Lymphoma, Sexual Dysfunction and Infertility, Sexuality and Reproductive Issues, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
laboratory biomarker analysis, fertility assessment and management, management of therapy complications, ultrasound imaging
Other · Procedure
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
14 Years to 35 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 16, 2026, 2:04 AM EDT
Terminated Phase 3 Interventional

A Phase III Study to Investigate if the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed With Type 1 Diabetes

NCT05018585
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Colecalciferol 2000 IU, Placebo
Biological · Dietary Supplement
Lead sponsor
Diamyd Medical AB
Industry
Eligibility
12 Years to 28 Years
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
13
States / cities
Newport Beach, California • Palo Alto, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VELOCITY: An Anthrax Vaccine Clinical Study

NCT03877926
View directory record Official record
Conditions
Anthrax
Interventions
AV7909, BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 31 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 16, 2026, 2:04 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases

NCT04119115
View directory record Official record
Conditions
Lung Diseases, Interstitial, Pulmonary Fibrosis
Interventions
CT-V, Metabolites
Device · Other
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated May 3, 2023 · Synced Oct 16, 2026, 2:04 AM EDT
Terminated Phase 3 Interventional Results available

Maximizing Outcome of Multiple Sclerosis Transplantation

NCT03342638
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting
Interventions
Cyclophosphamide, Mesna, rATG, Methylprednisolone, G-CSF, IVIg, Autologous Stem Cells
Drug · Biological
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 58 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 16, 2026, 2:04 AM EDT
Recruiting Phase 3 Interventional

An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC

NCT07720284
View directory record Official record
Conditions
High-risk Muscle Invasive Urothelial Carcinoma
Interventions
Dato-DXd, Rilvegostomig, Durvalumab, Nivolumab, Pembrolizumab, Enfortumab vedotin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
915 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
19
States / cities
Hot Springs, Arkansas • Little Rock, Arkansas • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Daily Stress and Vascular Function in Midlife as a Risk Factor for Cognitive Decline

NCT06466655
View directory record Official record
Conditions
Middle-aged Adults, Major Depressive Disorder
Interventions
MitoTempol, Lactated Ringer's (control)
Drug
Lead sponsor
University of Delaware
Other
Eligibility
40 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Newark, Delaware
Source: ClinicalTrials.gov public record
Updated Oct 2, 2025 · Synced Oct 16, 2026, 2:04 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Using Beta Blockers to Treat Mitral Regurgitation

NCT00700947
View directory record Official record
Conditions
Heart Disease, Mitral Regurgitation, Heart Valve Disease, Mitral Valve Insufficiency
Interventions
Beta-blocker therapy (TOPROL-XL® )
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 16, 2026, 2:04 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparing Bronchodilation of Symbicort With and Without Valved Holding Chamber (Aerochamber Plus)

NCT00915538
View directory record Official record
Conditions
Asthma
Interventions
pMDI budesonide/formotrol 160/4.5 is in group 1, Symbicort 160/4.5 plus Aerochamber Plus included in group 2
Drug · Device
Lead sponsor
Western Sky Medical Research
Other
Eligibility
18 Years to 60 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Aug 13, 2020 · Synced Oct 16, 2026, 2:04 AM EDT
Not listed No phase listed Observational

Using Wearable and Mobile Data to Diagnose and Monitor Movement Disorders

NCT04231487
View directory record Official record
Conditions
Essential Tremor, Parkinson Disease, Huntington Disease, Dystonia, Primary, Spinocerebellar Ataxias, Movement Disorders
Interventions
Not listed
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years to 80 Years
Enrollment
210 participants
Timeline
2019 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 16, 2026, 2:04 AM EDT
Recruiting Phase 2 Interventional

Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Standard Treatment

NCT07275216
View directory record Official record
Conditions
Classic Hodgkin Lymphoma
Interventions
Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Echocardiography Test, Gemcitabine, Pembrolizumab, Physical Performance Testing, Positron Emission Tomography, Pulmonary Function Test
Procedure · Drug · Biological + 1 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 16, 2026, 2:04 AM EDT
Completed No phase listed Observational

EFV Pharmacokinetics & Pharmacogenomics in Older HIV-infected Patients

NCT01886404
View directory record Official record
Conditions
HIV Infection
Interventions
Efavirenz
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Oct 16, 2026, 2:04 AM EDT